JAMES A GERAGHTY Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for JAMES A GERAGHTY.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of JAMES A GERAGHTY. JAMES A GERAGHTY is Director in JUNIPER PHARMACEUTICALS INC ($JNP) and Director in rEVO Biologics, Inc. ($GTCB) and Director in IDERA PHARMACEUTICALS, INC. ($IDRA) and in PIERIS PHARMACEUTICALS, INC. ($PIRS) and Director in PIERIS PHARMACEUTICALS, INC. ($PIRS) and Director in Voyager Therapeutics, Inc. ($VYGR) and Director in Fulcrum Therapeutics, Inc. ($FULC) and Director in Orchard Therapeutics plc ($ORTX).
Latest Insider Trading Transactions of JAMES A GERAGHTY
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, FULC, IDRA, JNP, ORTX, PIRS, GTCB, VYGR
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jun 17 2021 | ORTX | Orchard Therapeuti ... | GERAGHTY JAMES A | Director | Option Exercise | A | 4.79 | 40,000 | 191,600 | 40,000 | |
Jan 06 2021 | IDRA | IDERA PHARMACEUTIC ... | GERAGHTY JAMES A | Director | Grant | A | 4.02 | 4,851 | 19,501 | 104,770 | 99.9 K to 104.8 K (+4.85 %) |
Oct 05 2020 | IDRA | IDERA PHARMACEUTIC ... | GERAGHTY JAMES A | Director | Grant | A | 2.25 | 8,666 | 19,499 | 99,919 | 91.3 K to 99.9 K (+9.50 %) |
Jul 02 2020 | IDRA | IDERA PHARMACEUTIC ... | GERAGHTY JAMES A | Director | Grant | A | 1.79 | 10,894 | 19,500 | 91,253 | 80.4 K to 91.3 K (+13.56 %) |
Jun 25 2020 | PIRS | PIERIS PHARMACEUTI ... | GERAGHTY JAMES A | Option Exercise | A | 3.27 | 45,000 | 147,150 | 45,000 | ||
Jun 25 2020 | PIRS | PIERIS PHARMACEUTI ... | GERAGHTY JAMES A | Option Exercise | A | 3.27 | 45,000 | 147,150 | 45,000 | ||
Jun 19 2020 | ORTX | Orchard Therapeuti ... | GERAGHTY JAMES A | Director | Option Exercise | A | 7.81 | 35,000 | 273,350 | 35,000 | |
Jun 15 2020 | FULC | Fulcrum Therapeuti ... | GERAGHTY JAMES A | Director | Option Exercise | A | 17.63 | 9,285 | 163,695 | 9,285 | |
Jun 05 2020 | VYGR | Voyager Therapeuti ... | GERAGHTY JAMES A | Director | Option Exercise | A | 11.79 | 15,000 | 176,850 | 15,000 | |
May 19 2020 | IDRA | IDERA PHARMACEUTIC ... | GERAGHTY JAMES A | Director | Option Exercise | A | 1.97 | 14,500 | 28,565 | 14,500 | |
Apr 03 2020 | IDRA | IDERA PHARMACEUTIC ... | GERAGHTY JAMES A | Director | Grant | A | 1.28 | 14,926 | 19,105 | 80,359 | 65.4 K to 80.4 K (+22.81 %) |
Jan 28 2020 | PIRS | PIERIS PHARMACEUTI ... | GERAGHTY JAMES A | Option Exercise | A | 3.23 | 22,500 | 72,675 | 22,500 | ||
Jul 18 2019 | FULC | Fulcrum Therapeuti ... | GERAGHTY JAMES A | Director | Option Exercise | A | 16.00 | 9,285 | 148,560 | 9,285 | |
Jun 17 2019 | VYGR | Voyager Therapeuti ... | GERAGHTY JAMES A | Director | Option Exercise | A | 24.68 | 15,000 | 370,200 | 15,000 | |
Jun 06 2019 | IDRA | IDERA PHARMACEUTIC ... | GERAGHTY JAMES A | Director | Option Exercise | A | 2.57 | 14,500 | 37,265 | 14,500 | |
Jan 29 2019 | PIRS | PIERIS PHARMACEUTI ... | GERAGHTY JAMES A | Option Exercise | A | 2.74 | 25,000 | 68,500 | 25,000 | ||
Sep 12 2018 | VYGR | Voyager Therapeuti ... | GERAGHTY JAMES A | Director | Buy | P | 19.39 | 3,000 | 58,170 | 76,588 | 73.6 K to 76.6 K (+4.08 %) |
Aug 21 2018 | VYGR | Voyager Therapeuti ... | GERAGHTY JAMES A | Director | Buy | P | 18.31 | 3,000 | 54,930 | 73,588 | 70.6 K to 73.6 K (+4.25 %) |
Aug 15 2018 | JNP | JUNIPER PHARMACEUT ... | GERAGHTY JAMES A | Director | Option Exercise | D | 7.51 | 70,000 | 525,700 | 0 | |
Aug 15 2018 | JNP | JUNIPER PHARMACEUT ... | GERAGHTY JAMES A | Director | Option Exercise | D | 5.15 | 30,000 | 154,500 | 0 | |
Aug 15 2018 | JNP | JUNIPER PHARMACEUT ... | GERAGHTY JAMES A | Director | Sell | D | 11.50 | 80,747 | 928,591 | 0 | 80.7 K to 0 (-100.00 %) |
Aug 08 2018 | IDRA | IDERA PHARMACEUTIC ... | GERAGHTY JAMES A | Director | Buy | P | 5.58 | 10,000 | 55,800 | 65,433 | 55.4 K to 65.4 K (+18.04 %) |
Jul 05 2018 | IDRA | IDERA PHARMACEUTIC ... | GERAGHTY JAMES A | Director | Grant | A | 1.32 | 8,096 | 10,687 | 443,465 | 435.4 K to 443.5 K (+1.86 %) |
Jun 22 2018 | IDRA | IDERA PHARMACEUTIC ... | GERAGHTY JAMES A | Director | Option Exercise | A | 1.53 | 63,000 | 96,390 | 63,000 | |
Jun 18 2018 | VYGR | Voyager Therapeuti ... | GERAGHTY JAMES A | Director | Option Exercise | A | 21.64 | 15,000 | 324,600 | 15,000 | |
May 16 2018 | PIRS | PIERIS PHARMACEUTI ... | GERAGHTY JAMES A | Buy | P | 5.75 | 10,000 | 57,500 | 20,000 | 10 K to 20 K (+100.00 %) | |
Dec 14 2017 | PIRS | PIERIS PHARMACEUTI ... | GERAGHTY JAMES A | Option Exercise | A | 5.79 | 40,000 | 231,600 | 40,000 | ||
Aug 17 2017 | PIRS | PIERIS PHARMACEUTI ... | GERAGHTY JAMES A | Director | Buy | P | 4.82 | 10,000 | 48,200 | 10,000 | 0 to 10 K |
Jun 30 2017 | VYGR | Voyager Therapeuti ... | GERAGHTY JAMES A | Director | Option Exercise | A | 9.06 | 15,000 | 135,900 | 15,000 | |
Jun 09 2017 | IDRA | IDERA PHARMACEUTIC ... | GERAGHTY JAMES A | Director | Option Exercise | A | 1.63 | 63,000 | 102,690 | 63,000 | |
May 24 2017 | PIRS | PIERIS PHARMACEUTI ... | GERAGHTY JAMES A | Director | Option Exercise | A | 3.94 | 30,000 | 118,200 | 30,000 | |
Mar 20 2017 | JNP | JUNIPER PHARMACEUT ... | GERAGHTY JAMES A | Director | Buy | P | 4.82 | 2,000 | 9,637 | 65,153 | 63.2 K to 65.2 K (+3.17 %) |
Mar 07 2017 | JNP | JUNIPER PHARMACEUT ... | GERAGHTY JAMES A | Director | Option Exercise | A | 5.15 | 30,000 | 154,500 | 30,000 | |
Sep 14 2016 | JNP | JUNIPER PHARMACEUT ... | GERAGHTY JAMES A | Director | Buy | P | 5.97 | 2,000 | 11,930 | 63,153 | 61.2 K to 63.2 K (+3.27 %) |
Aug 24 2016 | JNP | JUNIPER PHARMACEUT ... | GERAGHTY JAMES A | Director | Buy | P | 6.03 | 2,937 | 17,716 | 61,153 | 58.2 K to 61.2 K (+5.05 %) |
Aug 24 2016 | JNP | JUNIPER PHARMACEUT ... | GERAGHTY JAMES A | Director | Buy | P | 5.90 | 4,063 | 23,972 | 58,216 | 54.2 K to 58.2 K (+7.50 %) |
Aug 03 2016 | JNP | JUNIPER PHARMACEUT ... | GERAGHTY JAMES A | Director | Grant | A | 0.00 | 10,613 | 0 | 54,153 | 43.5 K to 54.2 K (+24.38 %) |
Jul 06 2016 | IDRA | IDERA PHARMACEUTIC ... | GERAGHTY JAMES A | Director | Grant | A | 1.63 | 9,720 | 15,844 | 435,369 | 425.6 K to 435.4 K (+2.28 %) |
Jun 15 2016 | IDRA | IDERA PHARMACEUTIC ... | GERAGHTY JAMES A | Director | Option Exercise | A | 1.44 | 52,000 | 74,880 | 52,000 | |
May 16 2016 | IDRA | IDERA PHARMACEUTIC ... | GERAGHTY JAMES A | Director | Buy | P | 1.34 | 10,000 | 13,400 | 425,649 | 415.6 K to 425.6 K (+2.41 %) |
Nov 19 2015 | JNP | JUNIPER PHARMACEUT ... | GERAGHTY JAMES A | Director | Buy | P | 11.75 | 8,000 | 94,000 | 43,079 | 35.1 K to 43.1 K (+22.81 %) |
Oct 30 2015 | JNP | JUNIPER PHARMACEUT ... | GERAGHTY JAMES A | Director | Grant | A | 0.00 | 2,529 | 0 | 35,079 | 32.6 K to 35.1 K (+7.77 %) |
Aug 10 2015 | JNP | JUNIPER PHARMACEUT ... | GERAGHTY JAMES A | Director | Buy | P | 10.46 | 12,000 | 125,520 | 33,011 | 21 K to 33 K (+57.11 %) |
Jun 10 2015 | IDRA | IDERA PHARMACEUTIC ... | GERAGHTY JAMES A | Director | Option Exercise | A | 3.59 | 52,500 | 188,475 | 52,500 | |
Jun 02 2015 | JNP | JUNIPER PHARMACEUT ... | GERAGHTY JAMES A | Director | Buy | P | 8.38 | 20,550 | 172,209 | 0 | -20,550 to 0 (-100.00 %) |
Jun 01 2015 | JNP | JUNIPER PHARMACEUT ... | GERAGHTY JAMES A | Director | Option Exercise | A | 7.51 | 70,000 | 525,700 | 70,000 | |
Jun 01 2015 | JNP | JUNIPER PHARMACEUT ... | GERAGHTY JAMES A | Director | Grant | A | 7.51 | 461 | 3,462 | 461 | 0 to 461 |
Apr 06 2015 | IDRA | IDERA PHARMACEUTIC ... | GERAGHTY JAMES A | Director | Grant | A | 3.52 | 3,000 | 10,560 | 415,649 | 412.6 K to 415.6 K (+0.73 %) |
Jan 05 2010 | GTCB | rEVO Biologics, In ... | GERAGHTY JAMES A | Director | Grant | A | 0.75 | 4,000 | 3,000 | 19,025 | 15 K to 19 K (+26.62 %) |
Sep 28 2009 | GTCB | rEVO Biologics, In ... | GERAGHTY JAMES A | Director | Grant | A | 1.76 | 1,564 | 2,750 | 15,025 | 13.5 K to 15 K (+11.62 %) |
Jun 29 2009 | GTCB | rEVO Biologics, In ... | GERAGHTY JAMES A | Director | Grant | A | 2.70 | 1,019 | 2,751 | 13,461 | 12.4 K to 13.5 K (+8.19 %) |
Mar 31 2009 | GTCB | rEVO Biologics, In ... | GERAGHTY JAMES A | Director | Grant | A | 0.33 | 8,333 | 2,750 | 124,426 | 116.1 K to 124.4 K (+7.18 %) |
Dec 29 2008 | GTCB | rEVO Biologics, In ... | GERAGHTY JAMES A | Director | Grant | A | 0.28 | 9,874 | 2,750 | 116,093 | 106.2 K to 116.1 K (+9.30 %) |
Sep 29 2008 | GTCB | rEVO Biologics, In ... | GERAGHTY JAMES A | Director | Grant | A | 0.37 | 7,432 | 2,750 | 106,219 | 98.8 K to 106.2 K (+7.52 %) |
Jun 30 2008 | GTCB | rEVO Biologics, In ... | GERAGHTY JAMES A | Director | Grant | A | 0.40 | 6,841 | 2,750 | 98,787 | 91.9 K to 98.8 K (+7.44 %) |
Apr 01 2008 | GTCB | rEVO Biologics, In ... | GERAGHTY JAMES A | Director | Grant | A | 0.55 | 5,000 | 2,750 | 91,946 | 86.9 K to 91.9 K (+5.75 %) |
Dec 28 2007 | GTCB | rEVO Biologics, In ... | GERAGHTY JAMES A | Director | Grant | A | 0.87 | 3,161 | 2,750 | 86,946 | 83.8 K to 86.9 K (+3.77 %) |
Dec 17 2007 | GTCB | rEVO Biologics, In ... | GERAGHTY JAMES A | Director | Buy | P | 0.87 | 1,500 | 1,304 | 83,785 | 82.3 K to 83.8 K (+1.82 %) |
Dec 17 2007 | GTCB | rEVO Biologics, In ... | GERAGHTY JAMES A | Director | Buy | P | 0.87 | 1,700 | 1,478 | 82,285 | 80.6 K to 82.3 K (+2.11 %) |
Dec 17 2007 | GTCB | rEVO Biologics, In ... | GERAGHTY JAMES A | Director | Buy | P | 0.87 | 5,400 | 4,697 | 80,585 | 75.2 K to 80.6 K (+7.18 %) |
Dec 17 2007 | GTCB | rEVO Biologics, In ... | GERAGHTY JAMES A | Director | Buy | P | 0.87 | 1,400 | 1,216 | 75,185 | 73.8 K to 75.2 K (+1.90 %) |
Oct 02 2007 | GTCB | rEVO Biologics, In ... | GERAGHTY JAMES A | Director | Grant | A | 1.02 | 2,696 | 2,750 | 73,785 | 71.1 K to 73.8 K (+3.79 %) |
Jul 02 2007 | GTCB | rEVO Biologics, In ... | GERAGHTY JAMES A | Director | Grant | A | 1.15 | 2,391 | 2,750 | 71,089 | 68.7 K to 71.1 K (+3.48 %) |
Jul 02 2007 | GTCB | rEVO Biologics, In ... | GERAGHTY JAMES A | Director | Grant | A | 1.15 | 2,391 | 2,750 | 71,089 | 68.7 K to 71.1 K (+3.48 %) |
May 25 2007 | GTCB | rEVO Biologics, In ... | GERAGHTY JAMES A | Director | Option Exercise | A | 1.18 | 45,000 | 53,100 | 45,000 | |
Apr 03 2007 | GTCB | rEVO Biologics, In ... | GERAGHTY JAMES A | Director | Grant | A | 1.02 | 1,709 | 1,750 | 68,698 | 67 K to 68.7 K (+2.55 %) |
Jan 03 2007 | GTCB | rEVO Biologics, In ... | GERAGHTY JAMES A | Director | Grant | A | 1.11 | 1,577 | 1,750 | 66,989 | 65.4 K to 67 K (+2.41 %) |
Nov 16 2006 | GTCB | rEVO Biologics, In ... | GERAGHTY JAMES A | Director | Buy | P | 1.24 | 2,621 | 3,250 | 65,412 | 62.8 K to 65.4 K (+4.17 %) |
May 16 2005 | GTCB | rEVO Biologics, In ... | GERAGHTY JAMES A | Director | Buy | P | 1.32 | 3,000 | 3,960 | 59,791 | 56.8 K to 59.8 K (+5.28 %) |
Mar 15 2005 | GTCB | rEVO Biologics, In ... | GERAGHTY JAMES A | Director | Buy | P | 1.75 | 5,000 | 8,750 | 56,791 | 51.8 K to 56.8 K (+9.65 %) |
May 28 2004 | GTCB | rEVO Biologics, In ... | GERAGHTY JAMES A | Director | Option Exercise | A | 1.75 | 22,500 | 39,375 | 22,500 | |
Mar 19 2004 | GTCB | rEVO Biologics, In ... | GERAGHTY JAMES A | Director | Grant | A | 2.14 | 1,000 | 2,141 | 51,791 | 50.8 K to 51.8 K (+1.97 %) |
Page: 1